Processing

Please wait...

Settings

Settings

Goto Application

1. WO1993016102 - HUMAN CD26 AND METHODS FOR USE

Publication Number WO/1993/016102
Publication Date 19.08.1993
International Application No. PCT/US1992/002892
International Filing Date 09.04.1992
Chapter 2 Demand Filed 03.09.1993
IPC
C07K 14/705 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/40 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
C12N 9/16 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
C12N 9/48 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
48acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
CPC
C07K 14/70589
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70589CD45
C07K 16/289
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
289against CD45
C07K 16/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
40against enzymes
C12N 9/16
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes; Proenzymes; Compositions thereof
14Hydrolases (3)
16acting on ester bonds (3.1)
C12N 9/48
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes; Proenzymes; Compositions thereof
14Hydrolases (3)
48acting on peptide bonds (3.4)
Applicants
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
Inventors
  • MORIMOTO, Chikao
  • SCHLOSSMAN, Stuart, F.
  • TANAKA, Toshiaki
Agents
  • FRASER, Janis, K.
Priority Data
832,21106.02.1992US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HUMAN CD26 AND METHODS FOR USE
(FR) CD26 HUMAIN ET PROCEDES D'UTILISATION
Abstract
(EN)
A polypeptide fragment of CD26 (or analogs thereof) capable of disrupting the naturally-occuring binding interaction between CD45 and CD26, and a method of screening such compounds to identify compounds capable of inhibiting the binding of CD26 to CD45, which method includes the steps of: a) providing a first and a second sample of cells expressing both CD26 and CD45; b) incubating the first sample in the presence of a candidate compoud; c) incubating the second sample in the absence of the candidate compound; d) generating a first immunoprecipitate by adding to the first sample a first aliquot of an anti-CD26 antibody; e) generating a second immunoprecipitate by adding to the second sample a second aliquot of the antibody; and f) determining whether the amount of CD45 present in the first immunoprecipitate is less than the amount of CD45 present in the second immunoprecipitate, the presence of a lesser amount of CD45 in the first immunoprecipitate than in the second immunoprecipitate indicating that the candidate compound inhibits the binding.
(FR)
Fragment polypeptidique de CD26 (ou de ses analogues), pouvant détruire l'interaction de liaison naturelle entre CD45 et CD26, et procédé de triage de tels composés pour identifier des composés pouvant inhiber la liaison de CD26 à CD45, le procédé consistant à: a) prendre un premier et un second échantillon de cellules exprimant à la fois CD26 et CD45; b) incuber le premier échantillon en présence du composé potentiel; c) incuber le second échantillonen l'absence du composé potentiel; d) générer un premier immunoprécipité par l'addition d'une première aliquote d'un anticorps anti-CD26 au premier échantillon; e) générer un second immunoprécipité par l'addition d'une seconde aliquote de l'anticorps au second échantillon; et f) déterminer si la quantité de CD45 présent dans le premier immunoprécipité est inférieure à la quantité de CD45 dans le second immunoprécipité, la présence d'une quantité inférieure de CD45 dans le premier immunoprécipité, par rapport au second, indiquant que le composé inhibe la liaison.
Latest bibliographic data on file with the International Bureau